New antithrombotic agents

Panminerva Medica

Volumn 48, Issue 4, 2006, Pages 247-256

  Castelli, R ^a   Porro, F ^a   Savo, D ^a   Cassinerio, E ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute coronary syndromes; Thromboembolism; Thrombosis, drug therapy

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE DISEASE; ARTICLE; CORONARY ARTERY DISEASE; DRUG THERAPY; HUMAN; SYNDROME; THROMBOEMBOLISM;

ACUTE DISEASE; CORONARY DISEASE; DRUG THERAPY; FIBRINOLYTIC AGENTS; HUMANS; SYNDROME; THROMBOEMBOLISM;

EID: 33847623286     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Mahe I, Grenard AS, Joyeux N, Caulin C, Bergmann JF. Management of oral anticoagulant in clinical practice: a retrospective study of 187 patient. J Gerontol A Biol Sci Med Sci 2004;59:1339-4.
2. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005;39:632-6.
3. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005;127:922-7.
4. Wittkowsky AK. Factors associated with INR elevation and bleeding complications during warfarin therapy. Arch Intern Med 2005; 165:703.
5. Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B et al. Ad hoc Study Group of the Italian Federation of Anticoagulation Clinics. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005;129:72-6.
6. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005;77:365-72.
7. Veenstra DL, Blough DK, Higashi MK, Farm FM, Srinouanprachan S, Rieder MJ et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005;77:353-64.
8. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:2878-310S.
9. Bramlage P, Pittrow D, Kirch W. Current concepts for the prevention of venous thromboembolism. Eur J Clin Invest 2005;35 Suppl 1:4-11.
10. Blanchard E, Ansell J. Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism. Drugs 2005;65:303-11.
11. Monreal M, Zacharski L, Jimenez JA, Roncales J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004;2:1311-5.
12. Turpie AG, Norris TM. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thromb Haemost 2004;92: 3-12.
13. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C et al Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.
14. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005;10: 72-9.
15. Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vase Med 2004;9:205-13.
16. Mousa SA. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004;22:121-34.
17. Tiu A, Pang JM, Martin R, Officer N. Allergic reactions to enoxaparin and heparin: a case report and review of the literature. N Z Med J 2004;117:1126.
18. Basic-Jukic N, Kes P. Severe anaphylactic reaction in a haemodialysis patient after administration of reviparin. Neprhol Dial Transpl 2004; 19:1021-22.
19. Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G. Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovascular Surg 2003;126: 1194-5.
20. Mac Laughlin EJ, Fitzpatrick KT, Sbar E, Jewell C. Anaphylactoid reaction to enoxaparin in a patient with deep venous thrombosis. Pharmacotherapy 2002;22:1511-15.
21. BerkunY, HavivYS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004; 34:1916-18.
22. Fabris F, Sarfaz A, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia clinical and diagnostic implications. A review. Arch Pathol Lab Med 2000; 124: 1657-66.
23. Fabris F, Luzzato G, Stefani PM, Girolami B, Cella G, Girolami A. Heparin induced thrombocytopenia. Haematologica 2000; 85:72-80.
24. Deitcher SR, Barman TL. Heparin-induced thrombocytopenia: natural history, diagnosis and management. Vase Med 2001;6:113-9.
25. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cell. J Clin Invest 1994;93:81-8.
26. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin induced thrombocytopenia in patients with treated with low molecular weight or unfractionated heparin. N Engl J Med 1995;332:1330-5.
27. Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group. The incidence of heparin induced thrombocytopenia in medical patients treated with low molecular weight heparin : a prospective cohort study. Blood 2005;106:3049-54.
28. Petros S, Siegemund A, Enggelmann L. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolys 2006;17:131-7.
29. Pathak A, Zhao R, Monroe DM, Roberts HR, Sheridan BC, Selzman CH et al. Thrombin generation in vascular tissue. J Thromb Haemost 2006;4:60-7.
30. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997;99:2323-7.
31. Brunnee T, La Porta C, Reddigari SR, Salerno VM, Kaplan AP, Silverberg M. Activation of factor XI in plasma is dependent on factor XII. Blood 1993;8:580-6.
32. Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem 2000;27:20514-9.
33. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-12.
34. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23.
35. Shen GX. Inhibition of thrombin: relevance to antithrombosis strategy. Front Biosci 2006; 11:113-20.
36. Hassel K. The management of patients with heparin induced thrombocytopenia who require anticoagulant therapy. Chest 2005; 127: 1S-8S.
37. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
38. Schiele F, Vuillemenot A, Kramarz P, KiefferY, Anguenot T, Bernard Y et al. Use of recombinant hirudin as anti-thrombotic treatment in patients with heparin induced thrombocytopenia. Am J Hematol 1995;50:20-5.
39. Eriksson BI, Wille-Jørgensen P, Kälebo P, Mouret P, Rosencher N, Bosch P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
40. Choi TS, Khan AI Greilich PE, Kroll MH. Modified plasma based ecarin clotting time assay for monitoring recombinat hirudin during cardiac surgery. Am J Clin Pathol 2006;125:290-5.
41. Roguin A, Steinberg BA, Watkins SP, Resar Jr. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. Int J Cardiovasc Intervent 2005;7:1329-35.
42. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovascular Drugs 2005;5:291-305.
43. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90: 2385-9.
44. Potzach B, Madlaner K, Sellig C, Riess CF, Greinacher A, Muller Berghaus G: Monitoring of r-hirudin anticoagulation during cardiopulmonary by-pass: assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5.
45. Fischer KG; Lieb V, Hudek R, Piazolo L, HaaSe KK, BorggrefeM et al. Anti-hirudin antibodies alter pharmacocinetics and pharmacodymamics of recombinant hirudin. Thromb Haemost 2003;6:973-82.
46. Kolev K, Lerant I, Skopal J, Kelemen A, Nagy Z, Machovich R. Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome. Thromb Haemost 2005;94:82-7.
47. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005 ;6:1349-71.
48. Serruys PW, Vranckx P, Allikmets K. Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. Int J Clin Pract 2006;60:344-50.
49. Matthai WH Jr. Treatment of heparin-induced thrombocytopenia in cardiovascular patients. Expert Opin Pharmacother 2006;7:267-76.
50. West N. Bivalirudin: role in current percutaneous coronary intervention practice. Br J Hosp Med (London) 2005;66:687-9.
51. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhan N et al. Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovascular Pharmacol Ther 2005;10:209-10.
52. Rothman MT. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nat Clin Pract Cardiovasc Med 2005;2:465-74.
53. Katzen BT, Ardid MI, MacLean AA, Kovacs MF, Zemel G, Benenati JF et al. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vase Interve Radiol 2005:16:1183-7.
54. Serebruany MV, Malinin AI, Serebruany VL. Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. Expert Opin Pharmacother 2006;7:81-9.
55. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455-8.
56. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitors in rats, dogs and human. Drug Metab Dispos 2003;31:294-305.
57. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I et al. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-8.
58. Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vase Biol 2003;23:1491-500.
59. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001;161:2215-21.
60. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty : a randomized double-blind trial. Ann Intern Med 2002; 137:648-65.
61. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G et al. Comparison of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
62. Agnelli G, Sonaglia F, Becattini C. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Curr Pharm Des 2005; 11:3885-91.
63. Eriksson BI, BergqvistD, KäleboP, Dahl OE, Lindbratt S, Bylock A et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
64. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III Study. Thromb Haemost 2003;89:288-29.
65. Eriksson BI, Agnelli GA, Cohen AT, Dahl OE, Lassen MR, Mouret P et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1:2490-6.
66. Huisman MV, on behalf of the THRIVE II & V investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J Thromb Haemost 2003;Suppl 1.
67. Schulman S, Wählander K, Lundström, Billing Clason S, Eriksson H, for the Thrive HJ Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
68. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S et al., SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
69. Halperin JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 2005 ;45:1 -9.
70. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L et al. Hepatic findings in long term clinical trials of ximelagatran. Drug Saf 2005;28:351-70.
71. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P et al. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362;789-97.
72. Herbert JM, Herault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998;91:4197-205.
73. Gerotziafas GT, Samama MM. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 2005;11:3855-76.
74. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 2003;124:364S-70S.
75. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, Boyer-Neumann C et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-7.
76. Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Blood 2003;102:319.
77. Savi P, Chong B, Greinacher A, Gruel Y, Kelton JG, Warkentin TE et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood 2003;102:319.
78. Spinler SA. New concepts in heparin-induced thrombocytopenia: diagnosis and management. J Thromb Thrombolysis 2006;21:17-21.
79. Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK et al. Recombinant factor Vila reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003;1:2368-73.
80. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
81. Turpie AG, Bauer K, Eriksson B, Lassen M. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003;90:364-6.
82. Eriksson BI, Lassen MR, for the PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA-Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-42.
83. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. PEGASUS investigators Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005 ;92:1212-20.
84. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. ARTEMIS Investigators: Efficacy and safety of
85. fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9.
86. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-702.
87. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73.
88. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017 A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-24.
89. Simoons M, Lobo PI. The PENTUA Study: double-blind ranging study of fondaparinux (pentasaccharide) in unstable angina. Circulation 2001;104:lb-4b
90. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004;2:47-53.
91. Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC et al. Recombinant factor Vila reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-8.
92. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemostas 2004;2:612-8.
93. Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA et al. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemostas 2004;2:234-41.
94. Quan ML, Lam PY, Han, Pinto DJ, He MY, Li R et al. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2' dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-car-boxyamide dydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005;48:1729-44.
95. Leeand AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VII/tissue factor. J Intern Medicine 2003;3:209-23.
96. Vlasuk GP, Rote WE. Inhibition of Factor Vila/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc Med 2002;12:325-31.
97. Vlusak GP, Bradbury A, Lopez- Kinninger L, Colon S, Bergum PW, Maki S et al. Pharmacokinetinetics and anticoagulant properties of the factor Vila-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on stoichiometric binding to circulating factor X. Thromb Haemost 2003;99:803-12.
98. Moons AH, Peters RJ, Cate H, Bauer KA, Vlasuk GP, Buller HR et al. Recombinant nematode anticoagulant protein c2 a novel inhibitor of tissue factor-factor Vila activity, abrogates endotoxin-induced coagulation in chimpanzee. Thromb Haemost 2002;88:627-31.